Loading...
  • regenerate
  • Spontaneous recovery from ALF depends, in part, on the capacity of the liver to regenerate following acute injury ( 10 ) and that amplification of pro-inflammatory mediators in the regenerating tissue is also recognized to play an important role in limiting liver regeneration ( 11 ). (pubmedcentralcanada.ca)
  • We are now looking to expand this technology in the treatment of inflammatory conditions in vital organs beginning with the liver due to its unique ability to regenerate following injuries. (marketwired.com)
  • patient 's own liver to regenerate or to stabilize the patient until transplant. (bioportfolio.com)
  • hemodynamic
  • Based on 289 selected indicators and their effect on patient outcome following 8 categories were formed: general markers (n=32), bio-markers (n=131), hemodynamic (n=14), liver function tests (n=7), imaging/morphology (n=15), scoring systems (n=53), time intervals (n=17), and treatments (n=20). (sciencedomain.org)
  • bilirubin
  • The MELD score (based on bilirubin, creatinine, and INR) was first used to predict survival after transjugular portosystemic intrahepatic shunting [ 4 ] and was later validated as a predictor of mortality in patients awaiting LT in the USA and Europe [ 5 - 8 ]. (hindawi.com)
  • 3 times ULN: Withhold treatment until liver function tests return to baseline or ALT and AST ≤2.5 times ULN and total bilirubin ≤1.5 times ULN, then reinitiate at 750 mg once daily. (drugs.com)
  • Elevated hepatic transaminases, elevated bilirubin and prolonged PT/INR can be observed in liver profile. (explainmedicine.com)
  • 1993
  • The 1993 classification defines hyperacute as within 1 week, acute as 8-28 days and subacute as 4-12 weeks. (bionity.com)
  • mortality
  • Acute liver failure affects previously healthy and often young people and has a very high mortality due to rapid multi-organ failure. (frontiersin.org)
  • We propose a practical approach that can be used in Intensive Care Unit-equipped hospitals in resource-constrained countries to try and reduce the high mortality rate where liver transplantation is not available. (frontiersin.org)
  • The aim of this study was to compare the abilities of MELD, Child-Pugh (CP), and CanWAIT status to predict 3-month and 1-year mortality before LT in Canadian patients and to describe the use of MELD in Canada. (hindawi.com)
  • The MELD policy has resulted in fewer patients being listed for LT and fewer deaths on the waitlist without changing mortality rates following LT in the USA [ 9 , 10 ]. (hindawi.com)
  • Therefore, the primary purpose of this research was to validate the ability of the MELD score to predict mortality in a cohort of Canadian patients and to determine if MELD was superior to the CP score and CanWAIT status in predicting waitlist mortality. (hindawi.com)
  • Plasma concentration of glutamine is low in many patients with critical illness and a low level is an independent risk factor for mortality. (springeropen.com)
  • efficacy
  • Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov)
  • This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients. (clinicaltrials.gov)
  • A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov)
  • Acharya S, Bhatia V, Sreenivas V, Khanal S, Panda S (2009) Efficacy of L-Ornithine L-Aspartate in acute liver failure: a double-blind, randomised, placebo-controlled study. (springer.com)
  • In this study, researchers from Europe and the United States evaluated the safety and efficacy of the BAL in patients with severe acute liver failure. (gastrohep.com)
  • treatment
  • Bernal W, Hyyrylainen A, Gera A, Audimoolam V, Heaton N, Wendon J et al (2010) Evolution of natural history and treatment strategies in acute liver failure: lessons from a 35 year experiencein 3300 patients. (springer.com)
  • 3 times ULN occur during treatment in patients with baseline moderate hepatic impairment. (drugs.com)
  • Churchill) today announced that one of Sun Pharma's wholly owned subsidiary companies has received approval from the U.S. Food and Drug Administration (FDA) for YONSA ® (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). (businesswire.com)
  • YONSA ® (abiraterone acetate) in combination with methylprednisolone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). (businesswire.com)
  • We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. (tumorijournal.com)
  • To our knowledge, this is the first patient reported in the literature with hepatocellular carcinoma related to nonalcoholic steatohepatitis who died of rapid worsening of liver function during sorafenib treatment. (tumorijournal.com)